Allergic bronchopulmonary aspergillosis (ABPA) is an immunologically mediated pulmonary disorder resulting from a complex hypersensitivity reaction to airway colonization by the ubiquitous saprophytic fungus Aspergillus fumigatus1,2,3. Most commonly complicating the clinical course of patients with poorly controlled bronchial asthma or cystic fibrosis, ABPA is characterized by an exaggerated Th2-mediated immune response, recurrent pulmonary infiltrates, and progressive airway damage culminating in central bronchiectasis3,5,6. Because permanent structural lung injury can be averted through timely recognition and targeted anti-inflammatory and antifungal regimens, prompt diagnostic workup is imperative in susceptible populations3,6.

1. Etiology & Risk Factors

  • Primary Pathogen: Aspergillus fumigatus is the predominant causative organism, though other non-fumigatus Aspergillus species and fungi can trigger analogous allergic bronchopulmonary mycosis (ABPM)2,3.
  • Underlying Airway Disorders: Occurs almost exclusively in individuals with preexisting bronchial asthma (affecting an estimated 1-25% of asthmatic populations) and patients with cystic fibrosis (affecting up to 15%)3,5.
  • Host Genetic Predisposition: Polygenic susceptibility involving specific human leukocyte antigen (HLA) alleles (such as HLA-DR2 and HLA-DR4) and polymorphisms in genes regulating innate and adaptive immunity, such as surfactant proteins and interleukin receptors2,6.
  • Environmental Exposure: Inhalation of ubiquitous fungal conidia from decaying organic matter, damp indoor environments, or agricultural settings3,6.

2. Pathophysiology

The pathogenesis of ABPA represents a dysregulated host immune response to fungal antigens residing within the bronchial lumen without true tissue invasion3,5,6. Inhaled conidia germinate into hyphae that secrete various proteases, elastases, and allergens. In genetically susceptible hosts, these fungal proteins stimulate airway epithelial cells to release alarmins (such as thymic stromal lymphopoietin, IL-25, and IL-33), which subsequently activate dendritic cells and group 2 innate lymphoid cells (ILC2s)3,6. This primes a robust Th2-polarized CD4+ T-lymphocyte response characterized by the secretion of interleukin-4 (IL-4), IL-5, and IL-133,6. IL-4 and IL-13 stimulate B-cell class switching to produce massive quantities of Aspergillus-specific immunoglobulin E (IgE) and IgG. IL-5 mediates the recruitment, activation, and survival of eosinophils within the bronchial mucosa and lumen. The ensuing dense eosinophilic and lymphocytic infiltration, coupled with high concentrations of inflammatory cytokines and fungal proteases, damages the bronchial walls, paralyzes mucociliary clearance, and promotes dense mucus impaction. Over time, chronic destructive inflammation weakens the cartilaginous and muscular components of proximal and medium-sized bronchi, leading to the pathognomonic development of central bronchiectasis, irreversible airway remodeling, and pulmonary fibrosis if left untreated3,5,6.

Allergic bronchopulmonary aspergillosis — Pathophysiological Cascade & Clinical Flowchart 1 Trigger / Primary Insult Inhaled Aspergillus fumigatus conidia germinate in the bronchial tree, releasing antigens and provoking a local immune response 2 Cellular / Pathophysiological Cascade Th2-polarized CD4+ T lymphocytes and eosinophils drive a robust type-2 inflammatory cascade releasing interleukins-4, 5, and 13 3 Target Organ / Structural Change Chronic mucus hypersecretion, mucous plugging, and immune-mediated damage precipitate proximal and central airway destruction and bronchiectasis 4 Hallmark Clinical & Diagnostic Manifestation Patients present with refractory asthma exacerbations, expectoration of brownish mucus plugs, elevated total IgE, and fleeting radiographic opacities 5 Complications if Untreated & Therapeutic Target Glucocorticoids and antifungals target the immune response and fungal burden to prevent irreversible pulmonary fibrosis and respiratory failure

3. Clinical Presentation & Classic Clinical Signs

  • History & Cardinal Symptoms: Patients classically present with symptoms of poorly controlled or refractory bronchial asthma, characterized by chronic productive cough, severe wheezing, chest tightness, and dyspnea3,5,6. A hallmark feature is the expectoration of tenacious, brownish-black or golden-yellow mucus plugs (mucus casts of the bronchi)3,5. Low-grade fever, malaise, anorexia, and weight loss may accompany acute exacerbations5.
  • Physical Examination & Named Clinical Signs: Auscultation reveals generalized expiratory and inspiratory wheezes, often accompanied by coarse crepitations or crackles over areas of bronchial impaction and collapse. Signs of hyperinflation, prolonged expiration, and digital clubbing may be observed in advanced, long-standing disease with extensive bronchiectasis and chronic hypoxemia3,5.

4. Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Diagnostic Modality / Test Expected Clinical & Radiological / Laboratory Finding
Gold-Standard InvestigationHigh-resolution computed tomography (HRCT) demonstrating central bronchiectasis with normal tapering peripheral airways, combined with elevated Aspergillus-specific IgE and total serum IgE levels1,2,3.
Laboratory PanelMarkedly elevated total serum IgE (typically greater than 1,000 IU/mL), positive immediate cutaneous hypersensitivity skin test to Aspergillus antigen (type I reaction), elevated serum A. fumigatus-specific IgE and IgG, and peripheral blood eosinophilia (frequently exceeding 500-1,000 cells/mcL)1,2,3.
Imaging / Radiology (X-ray, US, CT, MRI)Chest radiography reveals fleeting (transient) pulmonary opacities, consolidation, atelectasis, tram-line shadows, band-like shadows (representing impacted bronchi), and "glove-finger" or "toothpaste" shadows. HRCT confirms central/proximal bronchiectasis, mucoid impaction, centrilobular nodules ("tree-in-bud" pattern), and high-attenuation mucus (HAM)3,5.
ECG / Histopathology / ProceduralSputum culture or PCR may yield A. fumigatus. Sputum cytology demonstrates eosinophils, Charcot-Leyden crystals, and fungal hyphae. Histopathology of bronchial biopsies reveals allergic mucin containing eosinophils, fungal elements, and mucin casts without tissue invasion1,3,5.

5. Staging, Classification & Clinical Scoring Systems

Criterion / Stage / Score Component Clinical Threshold, Points & Management Implication
ISHAM-ABPA Diagnostic CriteriaMandatory predisposition (asthma or cystic fibrosis) plus elevated A. fumigatus-specific IgE (or positive skin test) AND elevated total serum IgE (>1,000 IU/mL or two other criteria including precipitating antibodies, radiographic infiltrates, or eosinophilia)1,2.
Stage 1 (Acute)Classic clinical presentation with asthma symptoms, fleeting infiltrates, elevated IgE, peripheral eosinophilia, and positive specific IgE/skin tests. Responds to systemic corticosteroids1,3.
Stage 2 (Remission)Clinical and radiological stability with normal or significantly decreased total serum IgE levels maintained for at least 6 months off systemic corticosteroid therapy1,3.
Stage 3 (Exacerbation)Recurrence of clinical symptoms and fleeting pulmonary opacities accompanied by a twofold or greater rise in baseline total serum IgE levels, requiring treatment resumption1,3.
Stage 4 & 5 (Advanced / Fibrotic)Stage 4 represents severe asthma with corticosteroid dependence, while Stage 5 denotes end-stage fibrotic lung disease with irreversible respiratory impairment, extensive bronchiectasis, and cor pulmonale1,3.

6. Differential Diagnosis

Differential Condition Distinguishing Clinical, Biochemical & Imaging Features
Chronic Asthma / Severe Asthma with Type-2 InflammationPresents with wheezing and airflow obstruction, but lacks central bronchiectasis, fleeting opacities, elevated Aspergillus-specific IgE, and characteristic mucoid impaction3,5.
Cystic Fibrosis (CF)Can overlap with ABPA (up to 15% of CF patients develop ABPA), but distinguished by positive sweat chloride testing, genetic mutations in the CFTR gene, and pan-lobular or generalized bronchiectasis rather than isolated central predominance3,5.
Churg-Strauss Syndrome (Eosinophilic Granulomatosis with Polyangiitis, EGPA)Features adult-onset asthma, peripheral eosinophilia, and pulmonary infiltrates, but is distinguished by systemic vasculitic manifestations (mononeuritis multiplex, purpura, glomerulonephritis) and positive antineutrophil cytoplasmic antibodies (ANCA)3,5.
Chronic Pulmonary Aspergillosis (CPA) / AspergillomaOccurs predominantly in immunocompetent or mildly immunocompromised hosts with structural lung disease (e.g., prior tuberculosis, cavitary sarcoidosis) forming fungus balls within cavities, distinguished by high serum anti-Aspergillus precipitin/IgG titers and absence of allergic asthma or severe peripheral eosinophilia3,5.

7. Management & Treatment Protocol

  • Initial Stabilization & Resuscitation: Assess airway patency, provide supplemental oxygen for hypoxemia, and administer rapid-acting inhaled bronchodilators to relieve acute bronchospasm. Clear airway secretions using chest physiotherapy and postural drainage when appropriate3,5.
  • First-Line Medical / Pharmacological Therapy (with exact adult dosing):
    • Systemic Glucocorticoids: Oral prednisolone initiated at 0.5 mg/kg/day (or equivalent, e.g., 30-40 mg daily) as a single morning dose for 2 weeks, followed by alternate-day dosing or gradual tapering over 3 to 4 months based on clinical response and serum IgE levels1,2,3.
    • Antifungal Therapy (Adjunctive): Itraconazole administered at 200 mg orally twice daily for 16 weeks to reduce fungal burden, lower systemic steroid requirements, and decrease exacerbation frequency. Monitor liver function tests and check drug interactions via CYP3A4 pathway1,2,3.
    • Biologic Agents: Omalizumab (anti-IgE monoclonal antibody) or mepolizumab/benralizumab (anti-IL-5 therapy) serve as valuable steroid-sparing adjuncts for patients with glucocorticoid-dependent, treatment-refractory, or relapsing ABPA1,2,4,7.
  • Surgical / Interventional Indications: Reserved for rare complications such as massive hemoptysis arising from hypertrophied bronchial arteries (managed via bronchial artery embolization), localized destroyed lung segments, or suspected coexisting malignancy3,5.

8. Complications & Prognosis

  • Acute and Chronic Complications: Irreversible central bronchiectasis, recurrent atelectasis, severe respiratory failure, massive hemoptysis due to fungal angioinvasion or vessel erosion, pulmonary hypertension, cor pulmonale, and secondary bacterial or mycobacterial superinfections3,5.
  • Prognosis & Monitoring: Timely diagnosis and anti-inflammatory therapy prevent permanent structural damage and preserve pulmonary function. Total serum IgE serves as an essential biomarker for therapeutic monitoring, declining by at least 35% at 6-8 weeks following effective treatment initiation, whereas a twofold increase signals an impending exacerbation1,2,3.